Étiquette : épidémiologie

Cannabis consumption and the risk of psychosis, Alice Mulè et al., 2017

Cannabis consumption and the risk of psychosis Alice Mulè, Lucia Sideli, Giuseppe Colli, Laura Ferraro, Caterina La Cascia, Crocettarachele Sartorio, Fabio Seminerio, Giada Tripoli, Marta Di Forti, Daniele La Barbera, Robin Murray Evidence-based Psychiatric Care, 2017, 3, 25-31   Enfin, un article récent (novembre 2018) explorant la co-occurence "consommation de cannabis / troubles "psychotique"", qui plus est international (anglo-italien), et comprenant, parmi les signataires, les célèbres Robin Murray du Kings Collège londonien, et Marta Di Forti de l'Université de Palerme, qui énonce clairement l'incapacité épidémiologique à établir un lien de causalité entre "consommation de cannabis et éclosion de troubles "psychotique"" !!! : "Conclusions : The [...]

Lire la suite

Marijuana Use Continues to Grow in Older Adults, Pauline Anderson, Medscape, 26 February 2020

Marijuana Use Continues to Grow in Older Adults Pauline Anderson Medscape, February 26, 2020 https://www.medscape.com/viewarticle/925762?nlid=134178_2052&src=WNL_mdplsnews_200228_mscpedit_psyc&uac=292598PZ&spon=12&impID=2294726&faf=1   Cannabis use in older Americans is growing. New research shows that over a 4-year period use of the drug in individuals age 65 and older increased by 75%. Joseph J. Palamar, PhD, MPH This population is especially vulnerable to potential adverse effects from cannabis and so this population needs to understand the potential risks associated with marijuana use, study investigator Joseph J. Palamar, PhD, MPH, associate professor, Department of Population Health, New York University (NYU) Langone Medical Center, New York City, told Medscape Medical News. The findings, he added, indicate a need for more [...]

Lire la suite

Association of Depression, Anxiety, and Trauma With Cannabis Use During Pregnancy, Kelly C. Young-Wolff et al., 2020

Association of Depression, Anxiety, and Trauma With Cannabis Use During Pregnancy Kelly C. Young-Wolff, PhD, MPH; Varada Sarovar, PhD; Lue-Yen Tucker, BA; Nancy C. Goler, MD; Stacey E. Alexeeff, PhD; Kathryn K. Ridout,MD, PhD; Lyndsay A. Avalos, PhD JAMA Network Open, 2020, 3, (2), e1921333. doi : 10.1001/jamanetworkopen.2019.21333   Introduction Prenatal cannabis use is increasing,1,2 and several qualitative studies3,4 indicate that pregnantwomen self-report using cannabis to manage stress and mood. However, few epidemiological studies have examined whether pregnant women with mental health disorders and trauma are at increased risk of using cannabis during pregnancy. Data from the Kaiser Permanente Northern California (KPNC) large integrated health care [...]

Lire la suite

Canada : La consommation de cannabis des 15-17 ans a baissé de 47% depuis la légalisation, Newsweed, 20 février 2020, Aurélien BERNARD

Canada : La consommation de cannabis des 15-17 ans a baissé de 47% depuis la légalisation Newsweed, 20 février 2020 Par Aurélien BERNARD   Depuis la légalisation du cannabis au Canada en octobre 2018, Statistique Canada, l’organe statistique national, conduit tous les 3 mois une enquête pour récolter des données sur la consommation de cannabis des Canadiens. Malgré les limites inhérentes au déclaratif, ces données permettent d’entrevoir les effets de la légalisation sur les Canadiens. Consommation de cannabis selon l’âge Ainsi, après un an de légalisation, plus de 5,1 millions de Canadiens de 15 ans ou plus ont déclaré avoir consommé du cannabis en 2019 au cours [...]

Lire la suite

The epidemiology of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption, Alan K. Davis et al., 2018

The epidemiology of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption Alan K. Davis, Joseph P. Barsuglia, Rafael Lancelotta, Robert M. Grant, and Elise Renn Journal of Psychopharmacology, 2018, 32, (7), 779–792. doi : 10.1177/0269881118769063   Abstract Background/Aim : 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) is a psychoactive compound found in several plants and in high concentrations in Bufo alvarius toad venom. Synthetic, Toad, and Plant-sourced 5-MeO-DMT are used for spiritual and recreational purposes and may have psychotherapeutic effects. However, the use of 5-MeO-DMT is not well understood. Therefore, we examined patterns of use, motivations for consumption, subjective effects, and potential benefits and consequences [...]

Lire la suite

Psilocybin-Assisted Therapy : A Review of a Novel Treatment for Psychiatric Disorders, Kelan Thomas et al., 2017

Psilocybin-Assisted Therapy : A Review of a Novel Treatment for Psychiatric Disorders Kelan Thomas, Pharm.D., M.S., Benjamin Malcolm, Pharm.D., M.P.H., and Dan Lastra, B.S. Journal of Psychoactive Drugs, 2017 Doi : 10.1080/02791072.2017.1320734   Abstract Recent research suggests that functional connectivity changes may be involved in the pathophysiology of psychiatric disorders. Hyperconnectivity in the default mode network has been associated with psycho-pathology, but psychedelic serotonin agonists like psilocybin may profoundly disrupt these dysfunctional neural network circuits and provide a novel treatment for psychiatric disorders. We have reviewed the current literature to investigate the efficacy and safety of psilocybin-assisted therapy for the treatment of psychiatric disorders. There were [...]

Lire la suite

Risk of Persistence and Progression of Use of 5 Cannabis Products After Experimentation Among Adolescents, Jessica L. Barrington-Trimis, 2020

Risk of Persistence and Progression of Use of 5 Cannabis Products After Experimentation Among Adolescents Jessica L. Barrington-Trimis, PhD; Junhan Cho, PhD; Esthelle Ewusi-Boisvert, BA; Deborah Hasin, PhD; Jennifer B. Unger, PhD; Richard A. Miech, PhD; Adam M. Leventhal, PhD JAMA Network Open, 2020, 3, (1), e1919792. doi : 10.1001/jamanetworkopen.2019.19792   Abstract IMPORTANCE : While a diverse array of cannabis products that may appeal to youth is currently available, it is unknown whether the risk of persistent cannabis use and progression to higher frequency of use after experimentation differs among cannabis products. OBJECTIVE : To estimate the comparative relative risk of experimental use of 5 cannabis products [...]

Lire la suite

Association Between Recreational Marijuana Legalization in the United States and Changes in Marijuana Use and Cannabis Use Disorder From 2008 to 2016, Magdalena Cerdá et al., 2019

Association Between Recreational Marijuana Legalization in the United States and Changes in Marijuana Use and Cannabis Use Disorder From 2008 to 2016 Magdalena Cerdá, DrPH; Christine Mauro, PhD; Ava Hamilton, BA; Natalie S. Levy, MPH; Julián Santaella-Tenorio, DrPH; Deborah Hasin, PhD; Melanie M.Wall, PhD; Katherine M. Keyes, PhD; Silvia S. Martins, MD, PhD JAMA Psychiatry, 2019. doi : 10.1001/jamapsychiatry.2019.3254   IMPORTANCE : Little is known about changes in marijuana use and cannabis use disorder (CUD) after recreational marijuana legalization (RML). OBJECTIVES : To examine the associations between RML enactment and changes in marijuana use, frequent use, and CUD in the United States from 2008 to 2016. DESIGN, SETTING, AND [...]

Lire la suite

Associations Between Marijuana Use and Cardiovascular Risk Factors and Outcomes : A Systematic Review, Divya Ravi et al., 2018

Associations Between Marijuana Use and Cardiovascular Risk Factors and Outcomes : A Systematic Review Divya Ravi, MD, MPH; Mehrnaz Ghasemiesfe, MD; Deborah Korenstein, MD; Thomas Cascino, MD; and Salomeh Keyhani, MD, MPH Annals of Internal Medicine, 2018, 168, (3), 187-194. doi : 10.7326/M17-1548      Annals.org Abstract Background : Marijuana use is increasing in the United States, and its effect on cardiovascular health is unknown. Purpose : To review harms and benefits of marijuana use in relation to cardiovascular risk factors and clinical outcomes. Data Sources : PubMed, MEDLINE, EMBASE, PsycINFO, and the Cochrane Library between 1 January 1975 and 30 September 2017. Study Selection : Observational studies that were published [...]

Lire la suite